GO:0030251 guanylate cyclase inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030251 (guanylate cyclase inhibitor activity) describes a molecular function in which a protein or small molecule binds to and reduces the catalytic activity of a guanylate cyclase.
• Endogenous inhibitors include cyclophilin A (PPIA), which directly inhibits membrane-bound guanylate cyclase-A (GUCY1A3/GUCY1B3 heterodimer).
• Steroid hormones such as 17beta-estradiol can inhibit soluble guanylate cyclase through a protein tyrosine phosphatase-dependent mechanism in PC12 cells.
• Small-molecule inhibitors of soluble guanylate cyclase (sGC) have been developed for research and potential therapeutic use.
• Guanylate cyclase inhibitor activity is relevant to cardiovascular, pulmonary, and erectile biology, where cGMP signaling is central.
• Studying this activity requires assays that measure cGMP production, enzyme activity in lysates or permeabilized cells, and genetic models.
Description
Guanylate cyclase inhibitor activity (GO:0030251) is a molecular function that negatively regulates guanylate cyclases, the enzymes that convert GTP to cyclic GMP (cGMP). This activity is essential for fine-tuning cGMP-dependent processes such as smooth muscle relaxation, platelet aggregation, and neurotransmission. The term encompasses both endogenous protein inhibitors and exogenous small molecules that bind to and suppress guanylate cyclase catalytic activity. Researchers study this function to understand how cGMP levels are controlled in health and disease, and to develop pharmacological tools for conditions like pulmonary hypertension and erectile dysfunction. The QuickGO definition states that this activity 'binds to and stops, prevents or reduces the activity of guanylate cyclase.' This article synthesizes published findings on the mechanisms, key genes, and experimental approaches for investigating GO:0030251.
guanylate cyclase inhibitor activity At A Glance
| GO ID | GO:0030251 |
|---|---|
| GO term | guanylate cyclase inhibitor activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binds to and reduces the activity of guanylate cyclase enzymes |
| Major regulators | Cyclophilin A (PPIA), 17beta-estradiol, small-molecule inhibitors, ambroxol |
| Target enzymes | Membrane-bound guanylate cyclase-A (GUCY1A3/GUCY1B3), soluble guanylate cyclase (sGC) |
| Related processes | cGMP signaling, smooth muscle relaxation, platelet function, erectile dysfunction, pulmonary hypertension |
What Is GO:0030251?
Guanylate cyclase inhibitor activity (GO:0030251) is a molecular function in which a molecule (protein or small chemical) binds to a guanylate cyclase enzyme and decreases its ability to catalyze the conversion of GTP to cGMP. This inhibition can be direct, through physical interaction with the enzyme, or indirect, via modulation of associated regulatory pathways.
Why Is guanylate cyclase inhibitor activity Important in Cell Biology?
Guanylate cyclase inhibitor activity is critical for understanding how cGMP levels are controlled in cells. cGMP is a key second messenger in cardiovascular, pulmonary, and neuronal physiology, and its dysregulation contributes to diseases such as hypertension, pulmonary arterial hypertension, and erectile dysfunction. Endogenous inhibitors like cyclophilin A provide a mechanism for rapid, reversible modulation of cGMP production. Pharmacological inhibitors are valuable research tools and potential therapeutics. Studying GO:0030251 helps elucidate the molecular basis of cGMP homeostasis and identifies targets for drug development.
• Regulates cGMP levels, a central second messenger in smooth muscle relaxation and platelet inhibition.
• Cyclophilin A acts as an endogenous inhibitor of membrane-bound guanylate cyclase-A, linking to cardiovascular biology.
• 17beta-estradiol inhibits soluble guanylate cyclase via a protein tyrosine phosphatase in PC12 cells, connecting steroid signaling to cGMP.
• Small-molecule sGC inhibitors are used to probe cGMP-dependent pathways and have therapeutic potential.
• Guanylate cyclase inhibition is relevant to erectile dysfunction research, where sGC activators and PDE5 inhibitors are used.
• Pulmonary hypertension trials with guanylate cyclase stimulators highlight the importance of modulating this pathway.
• Ambroxol inhibits nitric oxide-dependent activation of soluble guanylate cyclase, linking drug effects to cGMP.
• Assays in human blood platelets and Dictyostelium discoideum provide model systems for studying guanylate cyclase regulation.
Molecular Mechanism of guanylate cyclase inhibitor activity
Direct binding to guanylate cyclase
In simple terms: An inhibitor molecule physically attaches to the guanylate cyclase enzyme and blocks its ability to make cGMP.
Cyclophilin A (PPIA) binds to membrane-bound guanylate cyclase-A and inhibits its activity, as shown in biochemical assays. This direct interaction reduces cGMP production, affecting downstream signaling. Small-molecule inhibitors such as those described by Mota et al. also bind to soluble guanylate cyclase and inhibit its catalytic function.
Indirect inhibition via phosphatases
In simple terms: Some inhibitors work by activating a phosphatase enzyme that removes phosphate groups from the guanylate cyclase, turning it off.
17beta-estradiol inhibits soluble guanylate cyclase activity in PC12 cells through a protein tyrosine phosphatase-dependent mechanism. This indirect pathway involves dephosphorylation of the enzyme or associated regulatory proteins, leading to reduced cGMP synthesis.
Inhibition of nitric oxide-dependent activation
In simple terms: Certain drugs prevent nitric oxide from turning on soluble guanylate cyclase.
Ambroxol acts as an inhibitor of nitric oxide-dependent activation of soluble guanylate cyclase, as demonstrated in biochemical studies. This suggests that some inhibitors target the activation step rather than the catalytic site directly.
Assays for guanylate cyclase inhibitor activity
In simple terms: Scientists measure how much cGMP is produced to see if an inhibitor is working.
Guanylate cyclase activity is commonly measured in lysates of human blood platelets or permeabilized Dictyostelium discoideum cells. These assays quantify cGMP formation from GTP and can be used to test potential inhibitors. Factors affecting enzyme activity, such as substrate concentration and cofactors, must be controlled.
Key Genes Involved in GO:0030251 guanylate cyclase inhibitor activity
The following genes and proteins are directly implicated in guanylate cyclase inhibitor activity or its regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPIA | Cyclophilin A, endogenous inhibitor of membrane-bound guanylate cyclase-A | Studied for cardiovascular effects and cGMP regulation |
| GUCY1A3 | Alpha subunit of soluble guanylate cyclase | Target of inhibitors; involved in cGMP signaling |
| GUCY1B3 | Beta subunit of soluble guanylate cyclase | Forms heterodimer with GUCY1A3; inhibited by small molecules |
| GUCY2C | Membrane-bound guanylate cyclase C | Potential target of endogenous inhibitors; not directly cited here |
| PTPN | Protein tyrosine phosphatase | Mediates 17beta-estradiol-induced inhibition of sGC |
| NOS1 | Neuronal nitric oxide synthase | Produces NO that activates sGC; inhibited indirectly by ambroxol |
| NOS3 | Endothelial nitric oxide synthase | Produces NO in vasculature; relevant to sGC regulation |
| PDE5A | Phosphodiesterase 5A | Degrades cGMP; target of inhibitors used in erectile dysfunction |
| PRKG1 | cGMP-dependent protein kinase I | Downstream effector of cGMP; affected by guanylate cyclase inhibition |
| RHO | Rho kinase | Involved in erectile dysfunction pathways; Rho-kinase inhibitors interact with sGC signaling |
| EDNRB | Endothelin receptor type B | Vasoconstriction pathways that may crosstalk with cGMP |
| ACE | Angiotensin-converting enzyme | Cardiovascular regulator; not directly cited but relevant to hypertension |
| ADRB2 | Beta-2 adrenergic receptor | Vascular tone regulation; potential crosstalk |
| CALM1 | Calmodulin | Regulates nitric oxide synthase and guanylate cyclase activity |
| GTP | Substrate for guanylate cyclase | Not a gene but central to assays |
| cGMP | Product of guanylate cyclase | Second messenger; readout of inhibitor activity |
| ATP | Energy source and phosphate donor | Affects enzyme activity in lysates |
How Is guanylate cyclase inhibitor activity Regulated?
Guanylate cyclase inhibitor activity is regulated at multiple levels. Endogenous inhibitors like cyclophilin A are expressed in a tissue-specific manner and can be induced under pathological conditions. Hormonal signals, such as 17beta-estradiol, modulate soluble guanylate cyclase through phosphatase-dependent pathways. Small-molecule inhibitors can be administered exogenously to acutely control cGMP levels. Additionally, nitric oxide availability influences the activation state of soluble guanylate cyclase, and inhibitors like ambroxol can interfere with this activation. The interplay between guanylate cyclases, phosphodiesterases, and protein kinases further shapes the overall cGMP signal.
guanylate cyclase inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPIA | Hypertension, cardiovascular dysfunction | PPIA knockout or overexpression in vascular smooth muscle cells |
| GUCY1A3 | Pulmonary hypertension, erectile dysfunction | Point mutations in catalytic domain; sGC inhibitor assays |
| PTPN | Steroid-responsive signaling in neurons | PC12 cells treated with 17beta-estradiol and phosphatase inhibitors |
| PDE5A | Erectile dysfunction | Knockout mice or cell lines with PDE5A overexpression |
| NOS3 | Endothelial dysfunction | Endothelial cell models with NOS3 knockout |
Cardiovascular disease and hypertension
Cyclophilin A functions as an endogenous inhibitor of membrane-bound guanylate cyclase-A, and this interaction may contribute to vascular dysfunction in hypertension. Reduced cGMP signaling is associated with impaired vasodilation, a hallmark of cardiovascular disease. Modulating guanylate cyclase inhibitor activity could therefore influence blood pressure regulation.
Pulmonary hypertension
Guanylate cyclase stimulators have been evaluated for pulmonary hypertension, highlighting the therapeutic importance of the cGMP pathway. Inhibitors of guanylate cyclase would oppose this effect, and understanding their activity is relevant for drug development and disease modeling.
Erectile dysfunction
Erectile function depends on cGMP-mediated smooth muscle relaxation. Rho-kinase inhibitors, soluble guanylate cyclase activators, and PDE5 inhibitors are novel approaches for erectile dysfunction. Guanylate cyclase inhibitor activity could counteract these beneficial effects, making it a target for research on erectile physiology.
Platelet function and thrombosis
Guanylate cyclase activity in human blood platelets is well documented. cGMP inhibits platelet aggregation, so inhibitors of guanylate cyclase may promote platelet activation. Studying this activity in platelets could reveal new insights into thrombotic disorders.
From guanylate cyclase inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PPIA directly inhibit guanylate cyclase-A? | Purified proteins in vitro; PPIA knockout cells |
| How does 17beta-estradiol inhibit sGC? | PC12 cells with protein tyrosine phosphatase knockdown |
| Can small molecules inhibit sGC in vivo? | Animal models of hypertension; sGC activity assays |
| What is the role of guanylate cyclase in platelets? | Human platelet lysates; knockout mouse platelets |
| How does ambroxol affect NO-dependent sGC activation? | Cell-free assays and cultured cells |
| Does guanylate cyclase inhibition affect erectile function? | Knockout mice for sGC subunits; PDE5A models |
How to Study the guanylate cyclase inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Guanylate cyclase activity assay | cGMP production from GTP | Testing inhibitors in lysates |
| Radioimmunoassay for cGMP | Intracellular cGMP levels | Platelet and cell studies |
| Fluorescent cGMP biosensor | Real-time cGMP dynamics | Live-cell imaging |
| Western blot | Protein expression and phosphorylation | Assessing PPIA or sGC levels |
| Knockout/knockdown | Gene function loss | Validating inhibitor targets |
| Overexpression | Gain of function | Sensitizing cells to inhibitors |
| Dose-response assay | IC50 of inhibitors | Drug development |
| Permeabilized cell assay | Enzyme activity in situ | Dictyostelium studies |
Enzyme activity assays
Guanylate cyclase activity is measured by incubating cell lysates or purified enzyme with GTP and quantifying cGMP production using radioimmunoassay or ELISA. These assays are used to test inhibitors and determine IC50 values.
Cell-based cGMP measurements
Intracellular cGMP levels can be measured in live cells using fluorescent biosensors or by lysing cells after treatment with inhibitors. This approach allows assessment of inhibitor activity in a physiological context.
Genetic manipulation
Knockout or knockdown of candidate inhibitor genes (e.g., PPIA) followed by cGMP measurement can establish causality. Overexpression of guanylate cyclase subunits can sensitize cells to inhibitors.
Pharmacological profiling
Small-molecule inhibitors are characterized using dose-response curves in enzyme and cell assays. Selectivity against other cyclases and phosphodiesterases is determined to ensure specificity.
How CRISPR Can Be Used to Study GO:0030251 guanylate cyclase inhibitor activity
Knockout
CRISPR knockout of PPIA or other candidate inhibitor genes can be used to determine whether loss of the inhibitor increases guanylate cyclase activity and cGMP levels. This approach provides causal evidence for endogenous inhibition.
Point Mutation
Introducing point mutations in the catalytic domain of guanylate cyclase (e.g., GUCY1A3) can reveal residues required for inhibitor binding. Such mutants help map the interaction interface.
Knock-in
Knock-in of tagged guanylate cyclase subunits (e.g., HA-tag) allows co-immunoprecipitation with inhibitor proteins like cyclophilin A. This facilitates identification of endogenous complexes.
Overexpression
Overexpression of guanylate cyclase or its inhibitor can be achieved via CRISPR activation or lentiviral delivery. This helps study dose-dependent effects on cGMP signaling.
How EDITGENE Supports guanylate cyclase inhibitor activity Research
Researchers studying guanylate cyclase inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in cGMP regulation. EDITGENE provides comprehensive CRISPR-based services to create knockout, point-mutation, knock-in, and overexpression cell models, enabling precise functional studies of GO:0030251.
Contact EDITGENE today to design your custom CRISPR model for guanylate cyclase inhibitor activity research.
Frequently Asked Questions About guanylate cyclase inhibitor activity
What is guanylate cyclase inhibitor activity?
It is a molecular function (GO:0030251) where a molecule binds to and reduces the activity of guanylate cyclase enzymes, decreasing cGMP production.
What genes are involved in guanylate cyclase inhibitor activity?
Key genes include PPIA (cyclophilin A), GUCY1A3, GUCY1B3, and PTPN, as well as small-molecule targets.
How is guanylate cyclase inhibitor activity measured?
It is measured by assaying cGMP production from GTP in cell lysates or permeabilized cells, often using radioimmunoassay or ELISA.
What diseases are associated with guanylate cyclase inhibitor activity?
It is linked to hypertension, pulmonary hypertension, erectile dysfunction, and platelet disorders.
Can CRISPR be used to study guanylate cyclase inhibitor activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect gene function in this pathway.
What is the role of cyclophilin A in guanylate cyclase inhibition?
Cyclophilin A (PPIA) acts as an endogenous inhibitor of membrane-bound guanylate cyclase-A, reducing cGMP production.
How does 17beta-estradiol inhibit soluble guanylate cyclase?
It inhibits sGC through a protein tyrosine phosphatase-dependent mechanism in PC12 cells.
Are there small-molecule inhibitors of soluble guanylate cyclase?
Yes, small-molecule inhibitors have been developed and characterized for research use.
What is the connection between guanylate cyclase and erectile dysfunction?
cGMP signaling is essential for erectile function; guanylate cyclase inhibitors would oppose relaxation, while activators and PDE5 inhibitors are used therapeutically.
How does ambroxol affect guanylate cyclase?
Ambroxol inhibits nitric oxide-dependent activation of soluble guanylate cyclase.
Conclusion
Guanylate cyclase inhibitor activity (GO:0030251) is a crucial molecular function for controlling cGMP levels in cardiovascular, pulmonary, and neuronal systems. Endogenous inhibitors like cyclophilin A and hormonal regulators such as 17beta-estradiol provide physiological mechanisms for fine-tuning guanylate cyclase activity. Small-molecule inhibitors offer research tools and potential therapeutic leads. Understanding this activity through CRISPR-based models and biochemical assays will advance our knowledge of cGMP-related diseases and guide drug discovery.
References
- 1. Chen ZJ et al.. 2004. Cyclophilin A functions as an endogenous inhibitor for membrane-bound guanylate cyclase-A.. Hypertension 44(6):963-8 PMID: 15466660
- 2. Adams AF et al.. 1978. Factors affecting the activity of guanylate cyclase in lysates of human blood platelets.. Biochem J 174(1):23-35 PMID: 29607
- 3. Chen ZJ et al.. 2001. 17beta-estradiol inhibits soluble guanylate cyclase activity through a protein tyrosine phosphatase in PC12 cells.. J Steroid Biochem Mol Biol 78(5):451-8 PMID: 11738555
- 4. Mota F et al.. 2015. A new small molecule inhibitor of soluble guanylate cyclase.. Bioorg Med Chem 23(17):5303-10 PMID: 26264842
- 5. Schoen CD et al.. 1996. Guanylate cyclase activity in permeabilized Dictyostelium discoideum cells.. J Cell Biochem 60(3):411-23 PMID: 8867816
- 6. Cellek S et al.. 2002. A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.. Expert Opin Investig Drugs 11(11):1563-73 PMID: 12437503
- 7. Wardle AJ et al.. 2016. Guanylate cyclase stimulators for pulmonary hypertension.. Cochrane Database Syst Rev 2016(8):CD011205 PMID: 27482837
- 8. Severina IS et al.. 2000. Ambroxol as an inhibitor of nitric oxide-dependent activation of soluble guanylate cyclase.. Eur J Pharmacol 407(1-2):61-4 PMID: 11050291
